Chemily, LLC is a research, development and consulting company focusing on cost-effective synthesis of glycan libraries, carbohydrate-based biochemicals, reagents and pharmaceuticals. CHEMILY is aiming at developing into a major supplier for carbohydrate-based biochemicals, reagents and pharmaceuticals, and has been manufacturing several categories of products using it's proprietary chemo-enzymatic and in vivo bioengineering technology. Some of the new developments include:1.Structure-defined oligosaccharides and glycolipids;2.Immunogenic bacterial cell surface polysaccharides;3.Sugar nucleotides and their derivatives;4.Carbohydrate-based pharmaceuticals and glycoprotein vaccines;5.Carbohydrate related enzymes, such as glycosyl transferases, glycosyl hydrolases, sugar nucleotide biosynthesized enzymes.Based on its proprietary carbohydrate and uncommon sugar library (deposits), CHEMILY has been developing sugar-containing small molecules in therapeutic treatment options in two core disease areas: cancer and cardiovascular diseases. Recently, CHEMILY has been licensing and developing novel glycoconjugation technology in order to produce polysaccharide-protein conjugate vaccines and therapeutic glycoproteins to unprecedented cost effective levels.